In contrast to solid tumors, hematological malignancies present lineage antigens like CD19, that can be targeted without the life-threatening consequences, as non-malignant cells expressing these antigens are dispensable (e.g. B-lymphocytes). Here, CD19 is linked to hematologic disorder.